{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:02:14Z","timestamp":1777478534708,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1124\/jpet.116.237388","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T02:29:29Z","timestamp":1478226569000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6\/2 Mouse Model of Huntington\u2019s Disease"],"prefix":"10.1016","volume":"360","author":[{"given":"Akina","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.237388_bib1","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u2019s disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.116.237388_bib2","series-title":"Dystonia - The Many Facets","first-page":"199","article-title":"Dystonia pathophysiology: a critical review","author":"Burbaud","year":"2012"},{"key":"10.1124\/jpet.116.237388_bib3","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1523\/JNEUROSCI.0388-12.2012","article-title":"R6\/2 Huntington\u2019s disease mice develop early and progressive abnormal brain metabolism and seizures","volume":"32","author":"Cepeda-Prado","year":"2012","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.116.237388_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nbd.2009.07.014","article-title":"CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington\u2019s disease","volume":"36","author":"Choi","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.116.237388_bib5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/jpet.116.237388_bib6","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1073\/pnas.1204542109","article-title":"Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice","volume":"109","author":"Crook","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.237388_bib7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","article-title":"Mouse models of Huntington\u2019s disease and methodological considerations for therapeutic trials","volume":"1792","author":"Ferrante","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.116.237388_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington\u2019s disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1124\/jpet.116.237388_bib9","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.237388_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JHD-2012-120009","article-title":"Functional differences between direct and indirect striatal output pathways in Huntington\u2019s disease","volume":"1","author":"Galvan","year":"2012","journal-title":"J Huntingtons Dis"},{"key":"10.1124\/jpet.116.237388_bib11","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease","volume":"5","author":"Giamp\u00e0","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.237388_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.nbd.2009.02.014","article-title":"Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington\u2019s disease","volume":"34","author":"Giamp\u00e0","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.116.237388_bib13","first-page":"282","article-title":"[Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]","volume":"4","author":"Gim\u00e9nez-Rold\u00e1n","year":"1989","journal-title":"Neurologia"},{"key":"10.1124\/jpet.116.237388_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/hmg\/ddg046","article-title":"Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice","volume":"12","author":"Gines","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.116.237388_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.116.237388_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0166-2236(90)90104-I","article-title":"Neurotransmitters and neuromodulators in the basal ganglia","volume":"13","author":"Graybiel","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.116.237388_bib17","doi-asserted-by":"crossref","first-page":"R509","DOI":"10.1016\/S0960-9822(00)00593-5","article-title":"The basal ganglia","volume":"10","author":"Graybiel","year":"2000","journal-title":"Curr Biol"},{"key":"10.1124\/jpet.116.237388_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchemneu.2003.10.003","article-title":"The primate basal ganglia: parallel and integrative networks","volume":"26","author":"Haber","year":"2003","journal-title":"J Chem Neuroanat"},{"key":"10.1124\/jpet.116.237388_bib19","doi-asserted-by":"crossref","first-page":"e0122197","DOI":"10.1371\/journal.pone.0122197","article-title":"Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor","volume":"10","author":"Harada","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.237388_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.65.4.436","article-title":"Dystonia and chorea in acquired systemic disorders","volume":"65","author":"Janavs","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.116.237388_bib21","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.1021\/jm5013648","article-title":"Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor","volume":"57","author":"Kunitomo","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.237388_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1531-8257(199901)14:1<95::AID-MDS1016>3.0.CO;2-8","article-title":"Dystonia in Huntington\u2019s disease: prevalence and clinical characteristics","volume":"14","author":"Louis","year":"1999","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.116.237388_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0166-4328(01)00261-3","article-title":"Evaluation of R6\/2 HD transgenic mice for therapeutic studies in Huntington\u2019s disease: behavioral testing and impact of diabetes mellitus","volume":"126","author":"L\u00fcesse","year":"2001","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.116.237388_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1124\/jpet.116.237388_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng882","article-title":"Disruption of CREB function in brain leads to neurodegeneration","volume":"31","author":"Mantamadiotis","year":"2002","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.116.237388_bib26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/jnr.23592","article-title":"Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer\u2019s disease","volume":"93","author":"Melief","year":"2015","journal-title":"J Neurosci Res"},{"key":"10.1124\/jpet.116.237388_bib27","doi-asserted-by":"crossref","first-page":"e99520","DOI":"10.1371\/journal.pone.0099520","article-title":"Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6\/2 and zQ175 mouse models of Huntington\u2019s disease","volume":"9","author":"Menalled","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.237388_bib28","doi-asserted-by":"crossref","first-page":"e9793","DOI":"10.1371\/journal.pone.0009793","article-title":"Comprehensive behavioral testing in the R6\/2 mouse model of Huntington\u2019s disease shows no benefit from CoQ10 or minocycline","volume":"5","author":"Menalled","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/jpet.116.237388_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J Comp Neurol"},{"key":"10.1124\/jpet.116.237388_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuron.2014.06.030","article-title":"ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6\/2 mice","volume":"83","author":"Naydenov","year":"2014","journal-title":"Neuron"},{"key":"10.1124\/jpet.116.237388_bib31","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1073\/pnas.0502177102","article-title":"Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington\u2019s disease mouse model","volume":"102","author":"Nguyen","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.237388_bib32","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.116.237388_bib33","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0306-4522(95)00596-X","article-title":"Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington\u2019s disease","volume":"72","author":"Norris","year":"1996","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.116.237388_bib34","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1124\/jpet.116.237388_bib35","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1523\/JNEUROSCI.1238-14.2015","article-title":"Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways","volume":"35","author":"Padovan-Neto","year":"2015","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.116.237388_bib36","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1124\/jpet.116.237388_bib37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","article-title":"Choosing an animal model for the study of Huntington\u2019s disease","volume":"14","author":"Pouladi","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.116.237388_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fnbeh.2013.00226","article-title":"Identification and optogenetic manipulation of memory engrams in the hippocampus","volume":"7","author":"Ramirez","year":"2014","journal-title":"Front Behav Neurosci"},{"key":"10.1124\/jpet.116.237388_bib39","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.116.237388_bib40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1124\/jpet.116.237388_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.116.237388_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0306-4522(94)00427-7","article-title":"Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington\u2019s disease using high resolution image analysis","volume":"64","author":"Sapp","year":"1995","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.116.237388_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res"},{"key":"10.1124\/jpet.116.237388_bib44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.115.230482","article-title":"The phosphodiesterase 10A selective inhibitor TAK-063 improves cognitive functions associated with schizophrenia in rodent models","volume":"356","author":"Shiraishi","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.237388_bib45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2307\/2529789","article-title":"A non-parametric equivalent of Williams\u2019 test for contrasting increasing dose levels of a treatment","volume":"33","author":"Shirley","year":"1977","journal-title":"Biometrics"},{"key":"10.1124\/jpet.116.237388_bib46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","article-title":"A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia","volume":"65","author":"Simpson","year":"2010","journal-title":"Neuron"},{"key":"10.1124\/jpet.116.237388_bib47","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.116.237388_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet"},{"key":"10.1124\/jpet.116.237388_bib49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.114.218552","article-title":"In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents","volume":"352","author":"Suzuki","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.237388_bib50","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1038\/npp.2016.20","article-title":"TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms","volume":"41","author":"Suzuki","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.116.237388_bib51","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbr.2008.01.001","article-title":"Procedural learning and cognitive flexibility in a mouse model of restricted, repetitive behaviour","volume":"189","author":"Tanimura","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.116.237388_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1124\/pr.58.1.7","article-title":"Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview","volume":"58","author":"Tardito","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.116.237388_bib53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation","volume":"328","author":"Threlfell","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.237388_bib61","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroscience.2016.10.006","article-title":"TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge","volume":"339","author":"Tomimatsu","year":"2016","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.116.237388_bib54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: widespread pathology in Huntington\u2019s disease","volume":"8","author":"van der Burg","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.116.237388_bib55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1124\/jpet.116.237388_bib56","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/jpet.116.237388_bib57","series-title":"Neurobiology of Huntington\u2019s Disease: Applications to Drug Discovery","first-page":"165","article-title":"Mouse models for validating preclinical candidates for Huntington\u2019s disease","author":"William Yang","year":"2011"},{"key":"10.1124\/jpet.116.237388_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2528930","article-title":"A test for differences between treatment means when several dose levels are compared with a zero dose control","volume":"27","author":"Williams","year":"1971","journal-title":"Biometrics"},{"key":"10.1124\/jpet.116.237388_bib59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuropharm.2015.08.008","article-title":"Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum","volume":"99","author":"Wilson","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.116.237388_bib60","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/hmg\/10.17.1829","article-title":"Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington\u2019s disease","volume":"10","author":"Wyttenbach","year":"2001","journal-title":"Hum Mol Genet"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524194852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524194852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.237388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:51:18Z","timestamp":1739994678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524194852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0022356524194852"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.237388","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6\/2 Mouse Model of Huntington\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.237388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}